Close Menu

North America

With the EUAs, a sample collection kit from Everlywell and tests from Gravity Diagnostics and Assurance Scientific may be used without a prescription.

With $1.2 billion in funding earmarked for more than 40 projects, the portfolio represents a path out of the SARS-CoV-2 pandemic for the US.

For the three months ended Dec. 31, 2020, the firm posted $34.5 million in revenues, up from $29.7 million in 2019 and beating analysts' estimate of $31.9 million.

The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.

The administration will expand COVID-19 testing for schools and underserved populations, increase manufacturing of testing supplies, and increase genomic sequencing.

Vikor has invested an undisclosed amount to help the startup commercialize a direct-to-consumer service that includes genomic risk testing and liquid biopsy cancer screening.

LifeLabs and Multiplex Genomics, a University of Guelph spinout, will work together to provide SARS-CoV-2 testing in Canada and track variants of the virus.

The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.

Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.

The point-of-care test is designed to detect antibodies against SARS-CoV-2 in a fingerstick blood sample.